Compare Heron Therapeutics Inc (HRTX) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Sibanye Stillwater Ltd — how do they compare? Heron Therapeutics Inc trades at $0.33 (market cap $61.47M), while Sibanye Stillwater Ltd trades at $10.76 (market cap $7.54B). The key difference: Sibanye Stillwater Ltd is far larger — about 122.7× Heron Therapeutics Inc's market cap, and Sibanye Stillwater Ltd pays a 2.93% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | SBSW | |
|---|---|---|
Market Cap | $61.47M | $7.54B |
Sector | Health | Basic Materials |
52-Week High | $1.49 | $21.12 |
52-Week Low | $0.32 | $7.27 |
Enterprise Value | $168.21M | $9.19B |
Dividend Yield | — | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
Sibanye Stillwater (SBSW) trades at $10.67, up 0.28% with a bullish technical signal despite recent earnings misses. The stock shows attractive valuation metrics with P/E of 4.76 and P/S of 0.94, though profitability remains challenged with negative net income margin of -3.99%. Recent news highlights significant price volatility and mixed analyst views on valuation.
The outlook suggests potential upside to the $14.25 consensus price target, supported by projected cash flow improvement in 2025. Key risks include persistent negative earnings, high debt levels, and commodity price sensitivity. Institutional sentiment leans bullish with 43% buy ratings, but investors should monitor execution on debt reduction targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
